Tweedie D J, Thomson A W, Horne C H
Biomedicine. 1978 Feb;29(1):1-3.
Growth of a syngeneic adenocarcinoma in C3H mice was investigated in animals receiving twice-daily subcutaneous injections of the antiprotease Trasylol. Development of primary tumours was not influenced by Trasylol treatment and the antiprotease did not affect concomitant ant--tumour immunity as assessed by resistance to secondary footpad challenge. From histological examination of tumours and a study of GVH (graft-versus-host) activity no evidence was gained that Trasylol treatment augments the host cellular immune response.
在接受每日两次皮下注射抗蛋白酶抑肽酶的C3H小鼠中，研究了同基因腺癌的生长情况。抑肽酶治疗对原发性肿瘤的发展没有影响，并且通过对二次足垫攻击的抵抗力评估，该抗蛋白酶不影响伴随的抗肿瘤免疫力。从肿瘤的组织学检查和移植物抗宿主（GVH）活性研究中，没有获得证据表明抑肽酶治疗增强了宿主细胞免疫反应。
